Furthermore, the reduced OXPHOS activity in HSF1-ablated LSCs, as well as the multitude of other functions driven by HSF1 that support cancer cell proliferation and survival18,58,71,72, points to HSF1 inhibition as a potential therapeutic alternative in AML. This evidence concerns the gene HSF1 and cancer.